Dataset from Phase 1: A Multi-Centered, Randomized, Blinded, Placebo-Controlled, Serial-Cohort, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of BG00010 (Neublastin) in Subjects With Sciatica

The primary objective of the study is to evaluate the safety, tolerability, and
pharmacokinetic (PK) profile of 3 intravenous (IV) injections of BG00010 given on 2 fixed
schedules; weekly and as frequently as every 48 hours (but no more than 3 times per week).

Secondary objectives of this study in this study population are to explore the repeated-dose
immunogenicity of BG00010 and to explore the potential of BG00010 to reduce pain following
multiple-dose administration.